RESEARCH MONOGRAPH · KDC-MN-368

Romosozumab

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

74/100

Anti-sclerostin antibody with the most striking BMD gains of any bone agent, complicated by a cardiovascular signal

Romosozumab is the bone agent that produced some of the most striking BMD gains in the field, and it's done so by exploiting a beautifully clean Wnt signaling story.

Sclerostin is an osteocyte-secreted Wnt pathway antagonist that binds LRP5 and LRP6 to suppress canonical Wnt signaling in bone. The clue this was a major regulator came from the rare human syndromes sclerosteosis and Van Buchem disease, where loss-of-function SOST mutations produce dramatically increased bone mass without obvious off-target pathology. The bone-specific phenotype made sclerostin one of the most compelling drug targets in osteoporosis biology, and the anti-sclerostin antibody approach was an obvious play.

Romosozumab is a humanized monoclonal that neutralizes circulating sclerostin, derepressing Wnt signaling in osteoblasts. The result is simultaneous activation of bone formation and suppression of resorption, which is mechanistically unusual because most anabolic agents (PTH analogs) activate resorption alongside formation. Romosozumab uncouples these two arms of bone remodeling for the duration of treatment.

The FRAME and ARCH trials are the clinical evidence base. FRAME (postmenopausal osteoporosis vs placebo, then transitioned to denosumab) showed roughly 73 percent reduction in vertebral fracture at 12 months, larger than any prior anabolic. ARCH (vs alendronate) showed similar fracture protection but with a cardiovascular event imbalance that prompted the black box warning. Whether the CV signal is real and how big it is remains contested, but the regulatory framing is conservative.

What's mechanistically interesting is the time-limited anabolic window. Romosozumab's bone-formation effect attenuates after about 12 months (similar to PTH analogs), which is why the clinical positioning is 12 months of treatment followed by antiresorptive maintenance. The biology of why the effect plateaus is partly about feedback compensatory mechanisms in osteocyte signaling.

Sourcing as a research antibody is limited. Romosozumab itself is proprietary, but anti-sclerostin antibodies and recombinant sclerostin for research use are available from multiple vendors for in vitro and mouse model work.

What we dont love is the cardiovascular safety signal complicating the risk-benefit framing. For postmenopausal women with severe osteoporosis the math probably works, but the indication has narrowed compared to where it could have been.

The Wnt pathway lessons here go beyond bone. Sclerostin biology has informed broader thinking about LRP-targeting therapies.

Evidence: 88
Mechanism: 92
Reliability: 85
Safety: 60
Sourcing: 60
Value: 55
Signal: 80
Staying power: 75

Plain-language summary Intrigue 72 / 100

Romosozumab, sold as Evenity, is a humanized antibody against sclerostin, a protein that osteocytes (bone cells embedded in mature bone) secrete to put a brake on the Wnt signaling pathway that promotes osteoblast bone formation. By neutralizing sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual-action mechanism unique among osteoporosis drugs. FDA-approved in 2019 for postmenopausal osteoporosis, it produces large bone density gains in twelve months. The label carries a black box warning for cardiovascular events based on a signal in the comparison-to-alendronate ARCH trial. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Anti-sclerostin monoclonal antibody

A humanized monoclonal antibody against sclerostin; a dual-action bone agent that increases formation and decreases resorption.

Abstract

Romosozumab (CAS 909395-70-6; humanized IgG2 monoclonal antibody against sclerostin; molecular weight approximately 145 kDa) is a humanized monoclonal antibody developed by Amgen and UCB and approved by the FDA in 2019 (Evenity). The compound binds sclerostin (a glycoprotein produced by osteocytes that inhibits Wnt signaling on osteoblasts), neutralizing its inhibitory effect on bone formation. Mechanism is dual-action: increased bone formation (Wnt pathway de-inhibition on osteoblasts) plus decreased bone resorption (reduced osteoclast differentiation), an unusual combination producing more rapid BMD gains than any other osteoporosis agent. Approved for postmenopausal osteoporosis at high fracture risk. The ARCH trial demonstrated superior fracture reduction versus alendronate. Cardiovascular safety signal (increased cardiovascular events versus alendronate in ARCH) led to a black-box warning; the compound is contraindicated in patients with recent myocardial infarction or stroke. Treatment duration is 12 months (loss of effect with longer treatment). Used as the canonical anti-sclerostin agent.

Mechanism of action

Anti-sclerostin monoclonal antibody; blocks osteocyte-derived Wnt inhibitor sclerostin. Dual-action: increased bone formation plus decreased resorption.

Reported research dose ranges

Clinical 210 mg subcutaneous for 12 months.

References

Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016.
Saag KG, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis (ARCH). N Engl J Med 2017.
Padhi D, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-368

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Romosozumab

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs